Cardioversion, Defibrillation, and Overdrive Pacing of Ventricular Arrhythmias: The Effect of Moricizine in Dogs with Sustained Monomorphic Ventricular Tachycardia

The purpose of this investigation is to define whether the antiarrhythmic drug moricizine has beneficial or adverse effects on currently used antitachycardia and antifibrillatory devices. These studies were performed in a dog model of sustained monomorphic ventricular tachycardia (VT). In 11 dogs, the left anterior descending artery and all surrounding epicardial collateral feeder vessels were ligated. Defibrillator patches were implanted and the dogs were allowed to recover. After a 7-day recovery period, effective refractory period (ERP), end diastolic threshold (EDT), VT induction, and VT and ventricular fibrillation (VF) termination data were collected before and after moricizine infusion (2 mg/kg). In this experimental model, moricizine caused the folIowing electrophysiological changes: a prolongation of the ERP from 173 ± 14 to 182 ± 15 fP < 0.02) with no significant effect on the EDT for pacing; a prolongation of the VT cycle length from 175 ± 18 to 201 ± 23 msec (P < 0.003); an increased cycle length required for overdrive pacing from 136 ± 20 to 157 ± 22 msec (P < 0.01); no effect on the energy required to cardiovert VT; an increase in the defibrillation threshold from 7.5 ±4 to 9.4 ± 4 joules (P < 0.006) and; in 5 of the 8 dogs with VT, theVT could be initiated with somewhat less aggressive stimulation. Significant beneficial electrophysiological effects were noted on theVT cycle length, including a proportionately prolonged overdrive pacing cycle length for VT termination. These changes were contrasted by the significant increase in the VF conversion energy required and the ease with which the VT could be induced postmoricizine. These findings suggest a possible proarrhythmic effect of moricizine.